" /> Pralsetinib - CISMeF





Preferred Label : Pralsetinib;

NCIt synonyms : (cis)-N-((S)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide;

NCIt definition : An orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor tyrosine kinase RET, with potential antineoplastic activity. Upon administration, pralsetinib binds to and targets various RET mutants and RET-containing fusion product. RET gene mutations and translocations result in the upregulation and/or activation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and regression of these cancers.;

UNII : 1WPE73O1WV;

InChIKey : GBLBJPZSROAGMF-BATDWUPUSA-N;

CAS number : 2097132-94-8;

Drug name : Gavreto;

Molecule name : BLU-667; BLU 667;

NCI Metathesaurus CUI : CL520212;

Codes from synonyms : 25527;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
07/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.